NAFLD与肝纤维化与美国普通人群股骨骨密度降低无关
该横断面研究基于2017-2018年NHANES数据,纳入925名男性和859名50岁以上参与者,采用VCTE评估肝脂肪变(CAP≥274 dB/m)和显著肝纤维化(LSM≥8 kPa),并同时进行股骨颈DXA。结果显示,调整年龄、BMI、种族、吸烟和糖尿病等混杂因素后,CAP或LSM均与男女骨密度降低无显著关联。
要点
- 肝脂肪变和显著纤维化在研究中患病率较高,但均未与股骨颈骨密度降低独立相关。
- 在未调整分析中,肝脂肪变与男女性骨质疏松患病率较低相关,但多因素调整后关联消失。
- 对于50岁以上美国人群,NAFLD或肝纤维化不应被视为股骨骨密度降低的独立风险因素。
核心结论
- 肝脂肪变和纤维化与美国50岁以上人群基于股骨DXA诊断的骨量减少或骨质疏松无关。
研究设计与样本
- 基于2017-2018年NHANES的横断面分析,纳入925名男性和859名50岁以上参与者,同时具备可靠VCTE和股骨颈DXA结果。
主要发现
- 肝脂肪变和显著纤维化患病率在男性中分别为53.1%和9.6%,在女性中分别为44.2%和8.0%。
- 单因素分析中,肝脂肪变与男女性骨质疏松患病率较低相关,而肝纤维化程度无差异。
- 调整年龄、BMI、种族/民族、吸烟和糖尿病后,CAP和LSM均与男女骨密度降低无显著关联。
关键数值与推荐
- CAP≥274 dB/m定义为肝脂肪变,LSM≥8 kPa定义为显著肝纤维化。
- 主要结局指标为提示骨量减少或骨质疏松的股骨颈BMD值。
临床怎么用
- 在评估50岁以上人群骨质疏松风险时,NAFLD或肝纤维化不应作为独立的骨密度降低风险因素。
- 对于NAFLD患者,仍需按常规指南进行骨密度筛查,但无需因肝病本身额外强化筛查。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
CONTEXT: It is still debated whether nonalcoholic fatty liver disease (NAFLD) may be a risk factor for reduced bone mineral density (BMD), and it is not known whether liver fibrosis, the major predictor of future development of liver-related events in NAFLD, has an influence on BMD. OBJECTIVE: To assess whether liver steatosis and fibrosis are associated with reduced BMD in the general US population. METHODS: We performed a cross-sectional analysis of the population-based 2017-2018 cycle of the National Health and Nutrition Examination Survey (NHANES), in which vibration-controlled transient elastography (VCTE) and dual-energy x-ray absorptiometry (DXA) of the femoral neck were simultaneously available. Controlled attenuation parameter (CAP) ≥ 274 dB/m was considered indicative of liver steatosis, while a median liver stiffness measurement (LSM) ≥ 8 kPa indicated the presence of significant liver fibrosis. We included all participants older than 50 years with reliable VCTE and femoral neck DXA results (925 men and 859 women). The main outcome measures were femoral neck BMD values indicative of osteopenia or osteoporosis. RESULTS: Steatosis and significant fibrosis were highly prevalent in the studied population, being present in 53.1% and 9.6% of men and 44.2% and 8.0% of women, respectively. In univariate analysis, liver steatosis was associated with a lower prevalence of osteoporosis in both men and women, while no difference was noted according to the degree of liver fibrosis. After adjustment for potential confounders, including age, BMI, race/ethnicity, cigarette smoking, and diabetes, neither CAP nor LSM were significantly associated with reduced BMD in both sexes. CONCLUSION: Liver steatosis and fibrosis are not associated with femoral DXA-based diagnosis of osteopenia or osteoporosis in the US population older than 50 years.
引用
- Ciardullo S, Muraca E, Zerbini F, et al. NAFLD and Liver Fibrosis Are Not Associated With Reduced Femoral Bone Mineral Density in the General US Population. J Clin Endocrinol Metab. 2021. PMID: 33878156. doi:10.1210/clinem/dgab262
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。